Leman Biotech Co., Ltd. announced the completion of a Series A+ financing round totaling nearly RMB 200 million (~ USD 29 million). The round was co‑led by Yuecai Holdings and XtalPi, with participation from Mony Valley, Tailong Capital, and individual investors. Existing shareholder Fuho Capital increased its stake. The proceeds will advance registrational Phase I trials of ultra‑low‑dose metabolically armored CAR‑T cell therapy and automated manufacturing scale‑up.
Financing Overview
Item
Detail
Company
Leman Biotech Co., Ltd.
Round
Series A+
Amount
~ RMB 200 million (~ USD 29 million)
Co‑Leads
Yuecai Holdings, XtalPi
New Investors
Mony Valley, Tailong Capital, individual financial investors
Existing Investor (Increased)
Fuho Capital
Use of Proceeds
Phase I registrational study; automated manufacturing; solid tumor translation
Improved persistence in hostile tumor microenvironment
Solid Tumor Targeting
Enhanced metabolic resilience
Addresses hypoxia, nutrient deprivation, immunosuppression in solid tumors
Automated Manufacturing
Closed‑system, scalable production
Cost reduction; batch consistency; global supply capability
Strategic Implications
CAR‑T Cost Revolution:Ultra‑low‑dose administration—enabled by metabolic armor technology—could reduce manufacturing costs 50‑70% vs. standard CAR‑T, addressing the primary barrier to global access (current CAR‑T priced at $300K‑$500K).
Solid Tumor Breakthrough: Traditional CAR‑T fails in solid tumors due to poor persistence; Leman’s metabolic engineering enables T‑cell survival in hypoxic, nutrient‑deprived microenvironments, potentially unlocking lung, gastric, and liver cancer indications.
XtalPi AI Synergy:XtalPi’s co‑lead investment suggests AI‑driven discovery collaboration—potentially applying machine learning to metabolic pathway optimization and patient selection biomarkers.
Registrational Phase I: The “registrational” designation implies pivotal trial readiness and accelerated regulatory pathway, potentially enabling China approval within 2‑3 years if efficacy and safety are confirmed.
Market Context
Factor
Impact
Global CAR‑T Market
~ $8 billion (2024); dominated by hematologic malignancies; solid tumor expansion is next frontier
Armoring T‑cells against tumor microenvironment hostility is emerging as key differentiator (e.g., CRISPR‑edited metabolic enzymes)
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase I enrollment, metabolic armor mechanism validation, and automated manufacturing scale‑up. Actual results may differ due to risks including solid tumor microenvironment complexity, competitive allogeneic CAR‑T development, and long‑term persistence data requirements.-Fineline Info & Tech
By Fineline Cube 